source
- Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypesIbrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…
- Phase III trial shows tebentafusp doubles five-year survival in untreated metastatic uveal melanomaA Phase III study of tebentafusp in patients with previously untreated metastatic uveal melanoma reported that five-year overall survival was roughly twice that of the control group. The trial als…